First Patient Dosed in the Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab with Recurrent Glioblastoma
Researchers have developed a technology that leverages the polio vaccine to help treat cancer for those who develop the disease later in life. The technology, conceived at Duke University and developed by Istari Oncology, uses antigens produced by the polio vaccine to trigger the immune system to eat away at targeted cancer cells.
Istari announced on November 30, 2020, the first patient was dosed in the LUMINOS-101 Phase 2 clinical trial, assessing the safety and efficacy of PVSRIPO in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda®) in patients with recurrent glioblastoma multiforme. PVSRIPO is a novel viral immunotherapy that activates a patient’s innate and adaptive immunity to facilitate a targeted anti-tumor immune response.